ARCA biopharma Inc (NASDAQ:ABIO) does about 243.35K shares in volume on a normal day but saw 289440 shares change hands in the recent trading day. The company now has a market cap of 34.82M USD. Its current market price is $2.40, marking a decrease of -4.00% compared to the previous close of $2.50. The 52 week high reached by this stock is $2.75 whilst the lowest price level in 52 weeks is $0.84.
ARCA biopharma Inc (ABIO) has a 20-day trading average at $3.18 and the current price is -12.73% off the 52-week high compared with 186.05% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.29 and its 200-day simple moving average is $2.56. If we look at the stock’s price movements over the week, volatility stands at 20.15%, which decreases to 11.96% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.80 to suggest the stock is neutral.
The consensus objective for the share price is $7.00, suggesting that the stock has a potential upside of 65.71% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 27, 2018 when Ascendiant Capital Markets initiated the stock to “Buy” and issued a price target of $2.
The current price level is 34.14%, 33.22%, and 74.12% away from its SMA20, SMA50, and SMA200 respectively, with the ABIO price moving below the 50-day SMA on current market day. ARCA biopharma Inc (ABIO) stock is up 7.27% over the week and 50.76% over the past month. Its price is 162.50% year-to-date and 116.63% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2020, with the company’s earnings per share (EPS) of -0.76 above consensus estimates by 0.54. The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 65.71 percent from here.
The company has a return on investment of -22.10% and return on equity of -20.05%. The beta has a value of 0.86. Price to book ratio is 1.07.
